title: Multiple apoptotic death types triggered through activation of separate pathways by cAMP and inhibitors of protein phosphatases in one (IPC leukemia) cell line.
abstract: The protein phosphatase inhibitors okadaic acid and calyculin A at moderate concentrations induced three types of apoptotic promyelocytic leukemia cell death, distinct with respect to ultrastructure and polynucleotide fragmentation. Calyculin A at higher concentrations (> 50 nM) induced a non-apoptotic death type with high ATP and pronounced micromitochondriosis. This suggests that protein phosphorylation pathways are involved in the triggering of several death pathways. Activation of the cAMP kinase induced yet another apoptotic death type, preferentially affecting cells in S-phase. In fact, cAMP acted in two ways to stop IPC promyelocyte proliferation: (1) block in late G1 (preventing new cells from entering DNA replication); and (2) induction of apoptosis in S-phase. cAMP and phosphatase inhibitors acted via distinct pathways. The inhibitors suppressed cAMP-induced death, but only at concentrations high enough to commit the cells to alternative, less conspicuous death types. The tumor-promoting activity of okadaic acid and calyculin A may therefore not be by protection against apoptosis. DNA fragmentation correlated with the novel feature of limited 28 S rRNA cleavage, suggesting co-ordinated polynucleotide cleavage, possibly directed against illegitimate polynucleotides, in some apoptotic death types.
authors.affiliation: University of Bergen, Medical School, Department of Anatomy and Cell Biology, Norway.
authors.forename: B T
authors.initials: BT
authors.lastname: Gjertsen
authors.forename: L I
authors.initials: LI
authors.lastname: Cressey
authors.forename: S
authors.initials: S
authors.lastname: Ruchaud
authors.forename: G
authors.initials: G
authors.lastname: Houge
authors.forename: M
authors.initials: M
authors.lastname: Lanotte
authors.forename: S O
authors.initials: SO
authors.lastname: Døskeland
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D002453:Cell Cycle; D002462:Cell Membrane / Q000473:pathology; D002467:Cell Nucleus / Q000473:pathology; D002843:Chromatin / Q000473:pathology; D000242:Cyclic AMP / Q000494:pharmacology*; D003593:Cytoplasm / Q000473:pathology; D004249:DNA Damage; D004305:Dose-Response Relationship, Drug; D004988:Ethers, Cyclic / Q000494:pharmacology; D015473:Leukemia, Promyelocytic, Acute / Q000378:metabolism*; D008387:Marine Toxins; D019319:Okadaic Acid; D010080:Oxazoles / Q000494:pharmacology; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors*; D012339:RNA, Ribosomal, 28S / Q000378:metabolism; D051381:Rats; D015398:Signal Transduction; D014407:Tumor Cells, Cultured
chemical_list: D002843:Chromatin; D004988:Ethers, Cyclic; D008387:Marine Toxins; D010080:Oxazoles; D012339:RNA, Ribosomal, 28S; D019319:Okadaic Acid; C059041:calyculin A; D000242:Cyclic AMP; D010749:Phosphoprotein Phosphatases